Avillion Announces US Approval of Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

December 19, 2017

Responsive image

LONDON, December 19, 2017 /PRNewswire/ —
Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announces that the U.S. Food and Drug Administration (FDA) today approved a…

Category: Precious Metals